Missed Opportunity for HIV Prevention Among a High-Risk Population of Women Experiencing Intimate Partner Violence
HIV pre-exposure prophylaxis (PrEP), a daily pill combining two antiretroviral agents, tenofovir disoproxil fumarate/emtricitabine (TDF/FTC), has been shown to be effective in preventing HIV transmission in men and women and is recommended for those at increased risk of HIV.1 Experience of intimate partner violence (IPV) increases HIV risk for women,2 and women receiving care in the Veterans Health Administration (VHA) experience substantial rates of IPV.3 Given this risk and the availability of PrEP as a prevention tool in VHA, we sought to examine the association between recent IPV exposure disclosed to VHA providers through routine screening and HIV diagnosis, testing, and PrEP prescriptions among this population.
Data were extracted from patient medical records through the VHA corporate data warehouse for all female patients routinely screened for past-year IPV across 13 VHA facilities between April 2014 and 2016 (for more information on study methods, see...
The authors thank Maggie Czarnogorski for the thoughtful contributions to the study design.
This study was funded by the U.S. Department of Veterans Affairs, Health Services Research and Development (VA HSR&D; IIR 15-142; PI: Dichter).
Compliance with Ethical Standards
Conflict of Interest
The authors declare that they do not have a conflict of interest.
- 1.US Centers for Disease Control and Prevention, US Public Health Service. Preexposure prophylaxis for the prevention of HIV infection in the United States—2017 update: a clinical practice guideline. Available at: https://www.cdc.gov/hiv/pdf/risk/prep/cdc-hiv-prep-guidelines-2017.pdf. Accessed May 2, 2019.